321 related articles for article (PubMed ID: 27696157)
1. Prolonged fibroblast growth factor 19 response in patients with primary sclerosing cholangitis after an oral chenodeoxycholic acid challenge.
Zweers SJ; de Vries EM; Lenicek M; Tolenaars D; de Waart DR; Koelfat KV; Groen AK; Olde Damink SW; Beuers U; Ponsioen C; Jansen PL; Schaap FG
Hepatol Int; 2017 Jan; 11(1):132-140. PubMed ID: 27696157
[TBL] [Abstract][Full Text] [Related]
2. Chenodeoxycholic acid stimulated fibroblast growth factor 19 response - a potential biochemical test for bile acid diarrhoea.
Borup C; Wildt S; Rumessen JJ; Bouchelouche PN; Graff J; Damgaard M; McQuitty C; Rainteau D; Munck LK
Aliment Pharmacol Ther; 2017 Jun; 45(11):1433-1442. PubMed ID: 28378364
[TBL] [Abstract][Full Text] [Related]
3. Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial.
Hirschfield GM; Chazouillères O; Drenth JP; Thorburn D; Harrison SA; Landis CS; Mayo MJ; Muir AJ; Trotter JF; Leeming DJ; Karsdal MA; Jaros MJ; Ling L; Kim KH; Rossi SJ; Somaratne RM; DePaoli AM; Beuers U
J Hepatol; 2019 Mar; 70(3):483-493. PubMed ID: 30414864
[TBL] [Abstract][Full Text] [Related]
4. Suppression of bile acid synthesis as a tipping point in the disease course of primary sclerosing cholangitis.
Braadland PR; Schneider KM; Bergquist A; Molinaro A; Lövgren-Sandblom A; Henricsson M; Karlsen TH; Vesterhus M; Trautwein C; Hov JR; Marschall HU
JHEP Rep; 2022 Nov; 4(11):100561. PubMed ID: 36176935
[TBL] [Abstract][Full Text] [Related]
5. The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance.
Schreuder TC; Marsman HA; Lenicek M; van Werven JR; Nederveen AJ; Jansen PL; Schaap FG
Am J Physiol Gastrointest Liver Physiol; 2010 Mar; 298(3):G440-5. PubMed ID: 20093562
[TBL] [Abstract][Full Text] [Related]
6. An FXR Agonist Reduces Bile Acid Synthesis Independently of Increases in FGF19 in Healthy Volunteers.
Al-Khaifi A; Rudling M; Angelin B
Gastroenterology; 2018 Oct; 155(4):1012-1016. PubMed ID: 29928896
[TBL] [Abstract][Full Text] [Related]
7. Response of fibroblast growth factor 19 and bile acid synthesis after a body weight-adjusted oral fat tolerance test in overweight and obese NAFLD patients: a non-randomized controlled pilot trial.
Friedrich D; Marschall HU; Lammert F
BMC Gastroenterol; 2018 Jun; 18(1):76. PubMed ID: 29866129
[TBL] [Abstract][Full Text] [Related]
8. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis.
Wunsch E; Trottier J; Milkiewicz M; Raszeja-Wyszomirska J; Hirschfield GM; Barbier O; Milkiewicz P
Hepatology; 2014 Sep; 60(3):931-40. PubMed ID: 24519384
[TBL] [Abstract][Full Text] [Related]
9. Obeticholic acid may increase the risk of gallstone formation in susceptible patients.
Al-Dury S; Wahlström A; Panzitt K; Thorell A; Ståhlman M; Trauner M; Fickert P; Bäckhed F; Fändriks L; Wagner M; Marschall HU
J Hepatol; 2019 Nov; 71(5):986-991. PubMed ID: 31254596
[TBL] [Abstract][Full Text] [Related]
10. Serum concentrations of 7alpha-hydroxy-4-cholesten-3-one reflect bile acid synthesis in humans.
Sauter G; Berr F; Beuers U; Fischer S; Paumgartner G
Hepatology; 1996 Jul; 24(1):123-6. PubMed ID: 8707250
[TBL] [Abstract][Full Text] [Related]
11. Loss of apical sodium bile acid transporter alters bile acid circulation and reduces biliary damage in cholangitis.
Meadows V; Marakovits C; Ekser B; Kundu D; Zhou T; Kyritsi K; Pham L; Chen L; Kennedy L; Ceci L; Wu N; Carpino G; Zhang W; Isidan A; Meyer A; Owen T; Gaudio E; Onori P; Alpini G; Francis H
Am J Physiol Gastrointest Liver Physiol; 2023 Jan; 324(1):G60-G77. PubMed ID: 36410025
[TBL] [Abstract][Full Text] [Related]
12. The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid.
Walters JR; Johnston IM; Nolan JD; Vassie C; Pruzanski ME; Shapiro DA
Aliment Pharmacol Ther; 2015 Jan; 41(1):54-64. PubMed ID: 25329562
[TBL] [Abstract][Full Text] [Related]
13. Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice.
Zhou M; Learned RM; Rossi SJ; DePaoli AM; Tian H; Ling L
Hepatology; 2016 Mar; 63(3):914-29. PubMed ID: 26418580
[TBL] [Abstract][Full Text] [Related]
14. Impaired Hepatic Adaptation to Chronic Cholestasis induced by Primary Sclerosing Cholangitis.
Milkiewicz M; Klak M; Kempinska-Podhorodecka A; Wiechowska-Kozlowska A; Urasinska E; Blatkiewicz M; Wunsch E; Elias E; Milkiewicz P
Sci Rep; 2016 Dec; 6():39573. PubMed ID: 28008998
[TBL] [Abstract][Full Text] [Related]
15. Lowered fasting chenodeoxycholic acid correlated with the decrease of fibroblast growth factor 19 in Chinese subjects with impaired fasting glucose.
Zhang J; Li H; Zhou H; Fang L; Xu J; Yan H; Chen S; Song Q; Zhang Y; Xu A; Fang Q; Ye Y; Jia W
Sci Rep; 2017 Jul; 7(1):6042. PubMed ID: 28729691
[TBL] [Abstract][Full Text] [Related]
16. Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis: A Human Pilot Study.
Assis DN; Abdelghany O; Cai SY; Gossard AA; Eaton JE; Keach JC; Deng Y; Setchell KD; Ciarleglio M; Lindor KD; Boyer JL
J Clin Gastroenterol; 2017 Feb; 51(2):e11-e16. PubMed ID: 27428727
[TBL] [Abstract][Full Text] [Related]
17. Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: A prospective observational study.
Appleby RN; Moghul I; Khan S; Yee M; Manousou P; Neal TD; Walters JRF
PLoS One; 2019; 14(1):e0211348. PubMed ID: 30682184
[TBL] [Abstract][Full Text] [Related]
18. No Gut No Gain! Enteral Bile Acid Treatment Preserves Gut Growth but Not Parenteral Nutrition-Associated Liver Injury in a Novel Extensive Short Bowel Animal Model.
Villalona G; Price A; Blomenkamp K; Manithody C; Saxena S; Ratchford T; Westrich M; Kakarla V; Pochampally S; Phillips W; Heafner N; Korremla N; Greenspon J; Guzman MA; Kumar Jain A
JPEN J Parenter Enteral Nutr; 2018 Nov; 42(8):1238-1251. PubMed ID: 29701901
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast growth factor 19 in patients with bile acid diarrhoea: a prospective comparison of FGF19 serum assay and SeHCAT retention.
Pattni SS; Brydon WG; Dew T; Johnston IM; Nolan JD; Srinivas M; Basumani P; Bardhan KD; Walters JR
Aliment Pharmacol Ther; 2013 Oct; 38(8):967-76. PubMed ID: 23981126
[TBL] [Abstract][Full Text] [Related]
20. Expression of hepatic Fibroblast Growth Factor 19 is enhanced in Primary Biliary Cirrhosis and correlates with severity of the disease.
Wunsch E; Milkiewicz M; Wasik U; Trottier J; Kempińska-Podhorodecka A; Elias E; Barbier O; Milkiewicz P
Sci Rep; 2015 Aug; 5():13462. PubMed ID: 26293907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
